Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

206.14 USD +3.79 (+1.87%)
Official Closing Price Updated: 7:58 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Lilly Completes Acquisition of Prevail Therapeutics
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery... 
From PR Newswire
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The... 
From PR Newswire
Thinking about trading options or stock in General Motors, Eli Lilly, CarMax, Micron Technology, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for GM, LLY, KMX, MU, and ROKU. 
From PR Newswire
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies,... 
From PR Newswire
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the... 
From PR Newswire
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts 
From PR Newswire
Gabrielle Sulzberger Elected to Lilly Board of Directors
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021. As a member of Lilly's board, she will serve on both the Audit... 
From PR Newswire
Thinking about trading options or stock in Blink Charging, Tesla, WW International, Inmode, or Eli Lilly?
InvestorsObserver issues critical PriceWatch Alerts for BLNK, TSLA, WW, INMD, and LLY. 
From PR Newswire
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic,... 
From PR Newswire
Thinking about trading options or stock in Eli Lilly, Gilead Sciences, GameStop, Boeing, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for LLY, GILD, GME, BA, and ROKU. 
From PR Newswire
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the... 
From PR Newswire
Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients... 
From PR Newswire
Further Research into Psilocybin Opens New Doors for Treatment
FinancialBuzz.com News Commentary 
From PR Newswire
(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?
From GlobeNewswire News Releases
Lilly to Participate in J.P. Morgan Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. David A. Ricks, Lilly's chairman and chief executive officer, will... 
From PR Newswire
(PRVL Alert) Johnson Fistel Investigates Proposed Sale of Prevail; Are Shareholders Getting a Fair Deal?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Prevail Therapeutics Inc. ("Prevail" or the "Company") (NASDAQ: PRVL) breached their... 
From PR Newswire
Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention
BLAZE-2 Study of bamlanivimab in COVID-19 is currently underway, among residents and staff of skilled nursing or assisted living facilities 
From PR Newswire
Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
Study will provide real-world data and insight on various infusion setting experiences 
From PR Newswire
PREVAIL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prevail Therapeutics Inc. - PRVL
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Prevail Therapeutics Inc. (NasdaqGS: PRVL) to... 
From PR Newswire
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
From GlobeNewswire News Releases
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
- Lilly expects to deliver strong financial and operational performance in 2021, highlighted by volume-based revenue growth, operating margin expansion, pipeline advancements and solid cash flow. 
From PR Newswire
Lilly Announces Agreement to Acquire Prevail Therapeutics
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address... 
From PR Newswire
Lilly Announces 15 Percent Dividend Increase
The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2021 will be $0.85 per share on... 
From PR Newswire
Lilly announces opening of patient enrollment for New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning study
- New IDEAS study will focus on African American and Latino participants 
From PR Newswire
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial... 
From PR Newswire
Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®
Pre-planned primary outcome analysis continues to show clinically significant improvement in invasive disease-free survival as data mature for people with HR+, HER2- high risk early breast cancer 
From PR Newswire
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
More than half of participants taking the highest dose achieved normal A1C levels, a key secondary endpoint in first phase 3 trial of SURPASS program 
From PR Newswire
Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement
Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2021 on Tuesday, December 15, 2020. Lilly will also conduct a conference call on that day with the investment community and... 
From PR Newswire
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology
62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.